Private equity firm Keensight says it no longer aims to strike a deal for the British medtech due to the ‘current ...

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

In the most recent trading session, Medtronic (MDT) closed at $82.90, indicating a +0.44% shift from the previous trading day.

Members of the Our Place Parkinson’s support group learned about a newly approved therapy offering more consistent symptom ...

The federal appellate court rejected an out-of-state employee's Minnesota Human Rights Act claims against her former ...

Truist lowered the firm’s price target on Medtronic (MDT) to $90 from $93 and keeps a Hold rating on the shares as part of a broad research ...

There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.

Dexcom has been cash flow positive for since 2014 and more recently moved into positive earnings territory. While revenue has grown very quickly, research and development expenses and selling, general ...

The following is a summary of “A prospective feasibility study to differentiate sacral neuromodulation lead electrode configurations using motor and sensory thresholds and locations of sensation,” ...

Working closely with risk analysis teams helps UX designers consider various use conditions that may not be immediately ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Intrinsic Therapeutics, which developed the Barricaid spine procedure, named Keith Valentine as president and CEO. Mr.